Hospital Mater Dei Earnings Call Transcripts
Fiscal Year 2026
-
Record Q1 2026 results with net revenue up 15% and EBITDA up 35% year-over-year, driven by higher average ticket, operational efficiency, and strong performance in oncology. Leverage improved, margins expanded, and disciplined capital allocation remains a priority.
Fiscal Year 2025
-
Record Q3 2025 results with net revenue of BRL 570 million and EBITDA up 39% year-over-year, driven by higher average ticket, operational efficiency, and strong performance in oncology and key units. Leverage reduced to 1.8x, with robust cash generation and continued focus on margin expansion.
-
Record Q2 2025 revenue and EBITDA were achieved through higher complexity procedures, operational efficiency, and disciplined cost control. Key units like Salvador and Nova Lima delivered strong growth, while leverage and cash flow improved, supporting further debt prepayment and expansion plans.
-
Record net revenue and margin improvements were achieved, driven by operational efficiency, strong performance in Salvador and Nova Lima, and growth in non-bed revenues. Cash flow enabled share buybacks and an extraordinary dividend, while Fitch reaffirmed the positive rating.
Fiscal Year 2024
-
2024 saw revenue and occupancy growth despite sector challenges, with cost pressures from regulatory changes and a focus on operational efficiency. New hospital ramp-ups and partnerships are set to drive margin recovery and cash generation in 2025.
-
A new hospital opening has driven positive operational results, while cost pressures from the Nursing Bill and NDI issues remain a challenge. Ongoing policy improvements and negotiations aim to enhance efficiency and financial performance.
-
Revenue grew 8.3% over H2 2023, but Q2 margins fell due to lower complexity, seasonality, and the nursing bill. July and August showed strong recovery, with improved mix and growth in surgeries, while divestment of Porto Dias and new projects support future profitability.